Chimeric Antigen Receptor Design in Human Mesenchymal Stromal Cells (CAR-MSCs) Mediates Homing to Target Sites and Downstream Immunosuppression for Immune Disease Treatment

Allogeneic mesenchymal stromal cell (MSC) therapy for immune disease is generally safe but often ineffective in clinical trials, in part due to poor trafficking and limited immunosuppression. To overcome these obstacles, we have created novel chimeric antigen receptor (CAR)-MSCs. We hypothesized that CAR-MSCs would show superior 1) homing to target tissues due to a tissue-specific antigen binding domain and 2) immunosuppression due to inclusion of immunosuppressive intracellular signaling domains.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 14 Source Type: research